Skip to content

Pharyngeal Sensitivity in Diagnosis Algorithm for Sleep Apnea Syndrome

Measurement of Pharyngeal Sensitivity With the SENSITEST Device: Validation of the Diagnosis Algorithm for Sleep Disordered Breathing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00885573
Acronym
SENSITEST
Enrollment
52
Registered
2009-04-22
Start date
2008-12-31
Completion date
2012-12-31
Last updated
2014-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndrome

Keywords

sleep apnea, pharyngeal sensitivity, pharyngeal dilator reflex, diagnosis algorithm, patients with suspected sleep apnea syndrome

Brief summary

Pharyngeal sensitivity is a determinant parameter of pharyngeal functioning, particularly regarding protective dilator reflexes of upper airway. Preliminary results have suggested that the use of this parameter in diagnosis algorithm such as linear discriminant analysis and random forest could predict the presence of sleep apnea syndrome in almost 98% of patients. Our study aims at validating a new diagnosis method of sleep disordered breathing which will be compared with nocturnal polysomnography, the reference method to diagnose sleep disordered breathing. Pharyngeal sensitivity will be measured using the SENSITEST device which allows an automatic measurement of the pharyngeal sensation. The use of this parameter in diagnosis algorithm will be compared with polysomnographic results.

Interventions

DEVICEMeasurement of pharyngeal sensitivity (SENSITEST)

Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.

Sponsors

University of Liege
CollaboratorOTHER
Poitiers University Hospital
CollaboratorOTHER
University Hospital, Geneva
CollaboratorOTHER
University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
30 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* consecutively included patients with suspicion of sleep apnea syndrome * patients who have signed the informed consent form * patients with body mass index less than or equal 30 kg/m2

Exclusion criteria

* body mass index more than 30 kg/m2 * pharyngeal infection or allergic rhinitis less than 2 weeks before recordings * craniofacial anomalies and/or limited mouth opening and/or teeth position compromising mouthpiece installation and stability during measurement * instable dentures * exaggerated gag reflex preventing pharynx examination * no visibility of the soft palate * systemic or topical anti-inflammatory treatments * treatments that may increase the occurence of nocturnal respiratory events and/or leading to daytime sleepiness and cognitive impairment * cardiac failure, or symptoms suggesting cardiac failure * history of stroke * contraindication for using xylocaine spray * no affiliation to national insurance * patient participating in another research study involving drugs that may interfere with sleep recordings and/or measurement of pharyngeal sensation * patient subjected to exclusion period following participation in another research study

Design outcomes

Primary

MeasureTime frame
We aim to compare the novel diagnosis method with nocturnal polysomnography which is the reference method to diagnose sleep disordered breathing.Measurement performed the morning following the nocturnal polysomnography

Secondary

MeasureTime frame
We will determine the severity of sleep apnea for which pharyngeal sensitivity is predictive of sleep apnea syndrome. To simplify the procedure, we will precise the role of pharyngeal anesthesia in the diagnostic predictive value of the algorithm.similar to primary outcome measure

Countries

France, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026